嘉事堂药业股份有限公司 关于前期会计差错更正后的财务报表 嘉事堂药业股份有限公司（以下简称"公司"）于 2026 年 03 月 13 日召开第 七届董事会第二十一次会议，审议通过了《关于对前期会计差错进行更正的议案》。 根据《企业会计准则第 28 号——会计政策、会计估计变更和差错更正》、中国证 券监督管理委员会《公开发行证券的公司信息披露编报规则第 19 号——财务信 息的更正及相关披露》、《深圳证券交易所股票上市规则》、《深圳证券交易所上市 公司自律监管指南第 1 号——业务办理》的相关规定，对前期会计差错进行更正 及追溯调整。2017 年至 2024 年更正后的年度报告财务报表如下（除特别注明外， 金额单位均为人民币元） 一、2017 年 1、合并财务报表 | 项目 | | 2017 年 12 月 31 日 | | | --- | --- | --- | --- | | | 更正前 | 更正金额 | 更正后 | | 应交税费 | 97,509,827.77 | 28,861,834.30 | 126,371,662.07 | | 其他应付款 | 250,872,613.50 | 8,275,931.51 ...

股票代码：002462 股票简称：嘉事堂 公告编号：2026-15 嘉事堂药业股份有限公司 关于召开 2025 年度股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年度股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市 规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法 律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2026 年 06 月 29 日 15:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 06 月 29 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投 票的具体时间为 2026 年 06 月 29 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2026 年 06 月 23 日 7 ...

证券代码：002462 证券简称：嘉事堂 公告编号：2026-06 嘉事堂药业股份有限公司 第七届董事会第二十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 嘉事堂药业股份有限公司（以下简称"公司""本公司"）第七届董事会第二 十一次会议于 2026 年 2 月 28 日以电子邮件的方式发出会议通知。会议于 2026 年 3 月 13 日 14 时以现场表决的方式召开。会议应表决的董事 9 名，实际表决的 董事 9 名。会议由董事长主持。本次会议的召开及表决程序符合《公司法》《公 司章程》及《董事会议事规则》的有关规定。 二、董事会会议审议情况 1、关于董事会 2025 年度工作报告的议案 同意 9 票，反对 0 票，弃权 0 票，议案获得通过。 2025 年是 "十四五"规划收官之年，也是"十五五"规划谋篇布局之年， 嘉事堂董事会严格遵循法律法规及公司章程，恪守受托责任，通过健全的科学决 策机制和动态监督体系，全面贯彻股东会决议事项，持续完善公司治理架构。全 体董事秉持勤勉尽责的职业准则，以专业素养履行治理职责，认真 ...

股票代码：002462 股票简称：嘉事堂 公告编号：2026-09 嘉事堂药业股份有限公司 关于 2025 年度利润分配预案的公告 若在分配预案实施前公司总股本由于可转债、股份回购、股权激励行权、再 融资新增股份上市等原因发生变化的，按照分配比例不变的原则对分配总额进行 调整。 三、现金分红预案的基本情况 公司最近一个会计年度净利润为正值，且合并报表、母公司报表年度末未分 配利润均为正值，最近三个会计年度 2023 年、2024 年、2025 年累计现金分红金 额高于最近三个会计年度年均净利润的 30%。因此公司不触及《深圳证券交易所 股票上市规则》第 9.8.1 条第（九）项规定的可能被实施其他风险警示的情形。 项目 本年度 上年度 上上年度 现金分红总额（元） 33,546,318.80 49,590,210.40 75,843,851.20 回购注销总额（元） 0.00 0.00 0.00 归属于上市公司股 东的净利润（元） 111,378,719.41 160,668,362.95 250,060,041.68 合并报表本年度末 累计未分配利润 （元） 2,540,587,255.75 母公司报表本年 ...

嘉事堂药业股份有限公司 2025 年年度报告全文 嘉事堂药业股份有限公司 2025 年年度报告 2026-08 【2026 年 3 月】 1 嘉事堂药业股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 公司负责人徐曦、主管会计工作负责人黄奕斌及会计机构负责人（会计 主管人员）林军声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 报告中对公司未来计划的前瞻性陈述不构成公司对投资者的实际承诺， 投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预 测与承诺之间的差异。 可能存在行业竞争、经营与管理、市场、国家政策等风险，敬请广大投 资者注意投资风险。 公司经本次董事会审议通过的利润分配预案为：以 291,707,120.00 为 基数，向全体股东每 10 股派发现金红利 1.15 元（含税），送红股 0 股（含 税），不以公积金转增股本。 2 | 目录 | | --- | | ...

Group 1 - The core point of the article is that as of February 13, 2026, the company has over 28,000 shareholders [2]

Core Viewpoint - The article highlights a significant trend in the A-share market, where there has been a surge in control changes among listed companies, reflecting increased market activity and strategic repositioning by various stakeholders [2][12]. Group 1: Control Changes in Listed Companies - Since 2025, at least 150 listed companies have announced plans for control changes, averaging one company every two days [2][3]. - As of 2026, over 60 companies have reported progress on control changes, indicating a continuation of this trend [2]. - The majority of control changes are occurring in traditional industries such as chemicals, textiles, and consumer goods, with acquirers including individuals, state-owned enterprises, and investment firms [2][5]. Group 2: Industry Distribution of Control Changes - The distribution of control changes shows that traditional industries dominate, with 12.77% of changes in the oil and petrochemical sector, and significant activity in environmental services, construction, and light manufacturing [5][7]. - Other sectors like agriculture, textiles, and real estate also show notable percentages of control changes, indicating a broad impact across various industries [5][7]. Group 3: Market Capitalization of Companies Involved - A significant portion of companies undergoing control changes are small-cap firms, with 169 companies having a market capitalization below 10 billion yuan, accounting for nearly 80% of the total [8][9]. - Companies with a market cap below 5 billion yuan represent 47.44%, while those between 5 billion and 10 billion yuan make up 31.16% [9][10]. Group 4: Motivations Behind Control Changes - The motivations for these control changes include financial distress among original controlling shareholders, strategic shifts in traditional industries, and pressures from debt [12][14]. - The trend is also driven by the need for new capital and resources to enhance company governance and operational efficiency [11][12]. Group 5: Types of Acquirers - The acquirers in these control changes are primarily state-owned enterprises, industrial capital, and limited partnership firms, with state-owned entities frequently taking over to optimize industrial layouts and stabilize the market [14]. - Industrial capital is also a significant player, often seeking to enhance synergies and expand into new business areas [14].

Group 1: Core Insights - Tongrentang Group is accelerating its capital deployment by planning to acquire Jiasitang for 1.461 billion yuan, aiming to fill its commercial distribution gap [2][3] - The group is also attempting to spin off Tongrentang Yiyang to the Hong Kong Stock Exchange, which would position it as the largest private traditional Chinese medicine hospital in China [2][6] - If both transactions are successful, Tongrentang will control five listed companies, creating a diversified capital structure across industry, commerce, and healthcare [2][3] Group 2: Financial Performance - Jiasitang reported a net profit of 161 million yuan in 2024, a decline of 35.75%, with revenue experiencing its first negative growth since listing at -19.93% [3][5] - Tongrentang's revenue and net profit both declined by 3.7% and 12.78% respectively in the first three quarters of 2025 [5] - Tongrentang Yiyang, despite being the largest private TCM hospital, has the lowest profitability within the group, with a gross margin of only 18.9% in 2024 [7][9] Group 3: Market Dynamics - The pharmaceutical industry is facing a slowdown, with revenue for major pharmaceutical manufacturing companies declining by 1.2% in 2025, prompting a trend of integration between manufacturing and distribution [6] - The merger between Tongrentang and Jiasitang is seen as a strategic move to enhance market coverage and operational synergy [6][5] - The integration of resources and optimization of management will be crucial for long-term success, as merely acquiring distribution channels may not suffice [6] Group 4: IPO Challenges - Tongrentang Yiyang has faced difficulties in its IPO process, having submitted its application twice without success, raising concerns about its independence and financial health [2][12] - The company’s profitability is heavily reliant on acquisitions, with a significant portion of its revenue coming from recently acquired assets [11][12] - The dual role of Tongrentang as both a supplier and a customer raises questions about the sustainability of its business model, which could hinder its IPO prospects [13]

Group 1 - Aier Eye Hospital clarified that it has no direct equity or operational management relationship with Xiangyang Hengtai Kang Hospital, which is a joint venture established by Aier Medical Investment Group and other investors [1] - Aier Medical Investment does not participate in the daily operations of Xiangyang Hengtai Kang Hospital, and there is no equity control or business relationship with Hunan Hengtai Kang Rehabilitation Medical Industry Development Co., Ltd [1] Group 2 - Eli Lilly reported a total revenue of $65.179 billion for 2025, a 45% year-on-year increase, with its star product, Tirzepatide, generating $36.507 billion in sales [2] - The company provided guidance for 2026, expecting revenue to reach between $80 billion and $83 billion, with non-GAAP EPS projected between $33.50 and $35.00 [2] Group 3 - Novo Nordisk's revenue for 2025 is projected to grow by 6% to 309.1 billion Danish Krone, with a 10% increase at fixed exchange rates [3] - Sales in the Greater China region for rare diseases grew by 84% year-on-year at fixed exchange rates, driven by sales in rare blood diseases [3] - The company plans to propose a dividend of 7.95 Danish Krone per share for 2025, totaling 11.70 Danish Krone for the year, and has initiated a stock buyback program of up to 15 billion Danish Krone [3] Group 4 - Innovent Biologics achieved total product revenue of approximately 11.9 billion Yuan in 2025, a year-on-year increase of about 45% [4] - The company expanded its oncology product portfolio to 13 products, with core products like Tyvyt (sintilimab injection) showing steady growth [4] - The company successfully entered the chronic disease commercialization field, with key products contributing significantly to revenue growth [5] Group 5 - Sequoia China completed the global acquisition of moxifloxacin business, establishing Hangzhou Sequoia Biopharmaceutical Co., Ltd, with former Pfizer executive Jin Xiaodong appointed as CEO [6] - The acquisition includes specific assets related to moxifloxacin, ensuring a solid foundation for the product's continued supply and future development [6] Group 6 - Jiashitang announced a change in its controlling shareholder to Tongrentang Group, following a share transfer agreement with Everbright Industrial and Everbright Health [7] - The transfer involves significant shareholdings, leading to a change in the actual controller to the State-owned Assets Supervision and Administration Commission of Beijing [7]

Core Viewpoint - Recently, Jiasitang announced that on February 2, 2026, its shareholders, Everbright Industrial and Everbright Health, signed a share transfer agreement with Beijing Tongrentang (Group) Co., Ltd. This transaction will result in a change of controlling shareholder to Tongrentang Group and the actual controller to the State-owned Assets Supervision and Administration Commission of the People's Government of Beijing Municipality [1] Group 1 - Everbright Industrial and Everbright Health will transfer 41,180,805 shares and 41,876,431 shares, respectively, to Tongrentang Group [1] - Following the completion of this transaction, the controlling shareholder of Jiasitang will change to Tongrentang Group [1] - The actual controller will be the State-owned Assets Supervision and Administration Commission of the People's Government of Beijing Municipality [1]